<!– imageTag: –>
<!– imageTagafter: and imageUrl: https://photos.prnewswire.com/prnvar/20150611/222368LOGO –>
HAMILTON, Bermuda, June 10, 2015 /PRNewswire/ — Axovant Sciences Ltd. (NYSE: AXON), a clinical-phase biopharmaceutical company, today announced the pricing of its first public supplying of 21,000,000 common shares at a fee of $15.00 per share. The common shares of Axovant Sciences Ltd. have actually been approved for listing on the brand-new York Stock Exchange and are expected to start trading under the ticker symbol “AXON” on June 11, 2015. Every one of the common shares are being readily available by Axovant Sciences Ltd. In addition, Axovant Sciences Ltd. has actually granted the underwriters a 30-day option to get up to 3,150,000 extra common shares.
Jefferies LLC, Evercore Group L.L.C. and RBC Capital Markets LLC are acting as joint book-operating managers for the offering. JMP Securities LLC is acting as lead manager, and Robert W. Baird & Co. Incorporated is acting as co-manager for the offering.
The supplying will certainly be gained just by means of a prospectus. As soon as available, copies of the last prospectus related to the supplying could be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 5twenty Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, telephone: (212) 653-9054 or email: email@example.com; or RBC Capital Markets, LLC, Attention: Prospectus Department, Brookfield Place, 200 Vesey Street 8th Floor, New York, NY 10281, telephone: (877) 822-4089, email: firstname.lastname@example.org.
A registration statement relating to these securities has actually been filed along with the Securities and Exchange Commission and was declared efficient on June 10, 2015. This press launch shall not constitute an supply to sell or the solicitation of an supply to get nor shall there be any kind of sale of these securities in any kind of point out or jurisdiction in which such offer, solicitation or sale would certainly be unlawful prior to registration or qualification under the securities laws of any kind of such point out or jurisdiction.
Axovant Sciences Ltd. is a clinical-phase biopharmaceutical business focused on the acquisition, progress and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Axovant intends to create a pipeline of product candidates to comprehensively manage the cognitive, behavioral and functional components of dementia, a condition characterized by substantial decline in psychological capacity and impaired day-to-day function.
SOURCE Axovant Sciences Ltd.